Emerging Biopharma

eyeball eye disease eyelash eyes
Biotech

Ollin eyes phase 3 after topping Vabysmo in early-stage trial

Given the findings, the Texas-based biotech is now planning to launch global phase 3 studies this year.
Gabrielle Masson Jan 8, 2026 3:20pm
Ron Park CEO

Addition Tx does the math and emerges from stealth with $100M

Dec 17, 2025 7:45am
yarrow

Yarrow blooms with $1.37B autoimmune thyroid disease deal

Dec 16, 2025 11:00am
graphic image of different colored hands shaking

Crescent inks $80M Kelun deal, adding ADC to mix with bispecific

Dec 4, 2025 9:50am
Winding 3D road with dollar bills

Protego tucks $130M series B into its fold

Dec 1, 2025 6:00am
Technology background with national flag of the United States

Federal commission warns that US is losing innovative edge

Nov 25, 2025 3:47pm
More News

Versant's Dayra dawns with $50M Biogen pact

Nov 24, 2025 10:28am

Lilly picks Philadelphia for newest Gateway Labs site

Nov 19, 2025 6:45am

Bayer opens Beijing incubator, names initial occupants

Nov 17, 2025 10:18am

Braveheart, with Biogen CEO on board, rallies $185M series A

Nov 5, 2025 7:51am